肺曲霉病会加重2019冠状病毒病吗?
本文总结现有证据提示重症COVID-19患者中可能存在曲霉共感染,包括已发表的COVID-19病例系列、病例描述及潜在生物学机制综述。已知流感相关肺曲霉病在ICU患者中发生且与死亡率增加相关,若COVID-19患者中亦存在曲霉共感染,则需早期临床怀疑和检测。文章提出COVID-19相关肺曲霉病作为一种可能的临床实体,并描述在重症监护环境中临床怀疑曲霉的理由。随着COVID-19大流行展开,需要关于此共感染存在的报告,并描述了将曲霉共感染病例贡献至进行中登记处的机会。
要点
- 重症COVID-19患者中曲霉共感染鲜有描述,但可能发生于收入ICU的COVID-19患者中。
- 流感相关肺曲霉病已知发生于需要重症监护的流感患者,并与死亡率增加相关。
- 若COVID-19患者中存在曲霉共感染,需早期临床怀疑和检测以理解流行病学并预防相关死亡。
- 随着大流行展开,需要关于此共感染存在的报告,并可将曲霉共感染病例贡献至进行中的登记处。
适用人群与场景
- 收入ICU的重症COVID-19患者。
研究设计与关键结果
- 本文总结已发表的COVID-19病例系列、病例描述及潜在生物学机制综述,提出COVID-19相关肺曲霉病作为一种可能的临床实体。
- 流感相关肺曲霉病已知发生于需要重症监护的流感患者,并与死亡率增加相关。
- 若COVID-19患者中存在曲霉共感染,需早期临床怀疑和检测以理解流行病学并预防相关死亡。
证据类型、等级与局限
- 证据类型:综述(总结已发表的COVID-19病例系列、病例描述及潜在生物学机制)。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,在重症监护环境中临床怀疑曲霉是合理的,若COVID-19患者中存在曲霉共感染,早期临床怀疑和检测是需要的。
- 作者认为,随着COVID-19大流行展开,需要关于此共感染存在的报告,并可将曲霉共感染病例贡献至进行中的登记处。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Aspergillus coinfection in coronavirus disease 2019 patients has rarely been described but may be occurring among coronavirus disease 2019 patients admitted to ICUs. Previous reports of viral coinfections with Aspergillus, including influenza-associated pulmonary aspergillosis, suggest that coronavirus disease 2019-associated aspergillosis is plausible. This report aims to summarize what is known about coronavirus disease 2019 complicated by Aspergillus, introduces coronavirus disease 2019-associated pulmonary aspergillosis as a possible clinical entity, and describes reasons clinical suspicion of Aspergillus is warranted in the critical care setting.
DATA SOURCES: We summarize the available evidence suggesting the existence of Aspergillus coinfection among severe coronavirus disease 2019 patients. This includes published coronavirus disease 2019 patient case series, a case description, and a review of potential biologic mechanisms.
STUDY SELECTION: Reports of coronavirus disease 2019 patient attributes were selected if they included clinical, microbiologic, or radiologic signs of invasive fungal infection.
DATA EXTRACTION: Data included in summary tables were identified through a literature search for coronavirus disease 2019-associated pulmonary aspergillosis.
DATA SYNTHESIS: We present descriptive data extracted from coronavirus disease 2019-associated pulmonary aspergillosis case series current at the time of article submission.
DISCUSSION: Pulmonary aspergillosis is known to occur among influenza patients requiring intensive care and is associated with increased mortality. If Aspergillus coinfections are occurring among coronavirus disease 2019 patients, early clinical suspicion and testing are needed to understand the epidemiology of these infections and prevent associated mortality. As the coronavirus disease 2019 pandemic unfolds, reports on the existence of this coinfection are needed, and opportunities to contribute cases of Aspergillus coinfection among coronavirus disease 2019 patients to an ongoing registry are described.
参考来源
- Beer KD, Jackson BR, Chiller T, et al. Does Pulmonary Aspergillosis Complicate Coronavirus Disease 2019? Crit Care Explor. 2020. PMID: 32984834. doi:10.1097/CCE.0000000000000211
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。